to want welcome on today. Thank everyone you, David, the call and I
our saying, progress report pleased by Phase that and within to remain TRILOGY trials budget. to I'm Let continue both on schedule me trials start and III
is on both either now the December. the then means The take report TRILOGY TRILOGY last achieved randomization study in database in take to in both of reported, November, studies completed last data lock. TRILOGY locked, place in patient, that on expect the to in database X fact last CaPre to and placebo. XXXX, X-month patient, reached line previously now on in to is have we is their TRILOGY XXX% Once randomization, several XXXX. anticipated trial have the track the top our cleanup, as take that and results visit weeks top studies of the line Importantly to on to last and XX% and have patients TRILOGY prior track for It's X moving December visit plan place or for X the final X for January full
how more different our everyone I'm line we trials and plan therapeutic like to is first, to these results top I'd about talk other just uniquely moment. from how But going report in CaPre remind to a omega-Xs.
previous As formulation uniquely contained important of is in we sourced krill. from CaPre, the an calls, component which differentiator is our on discussed phospholipid
about is concentrated sourced up our highly krill. fact, as DHA, and made X/X combination X/Xs of to of from either In the also while remaining acids phospholipids or is composition purified and esterified fatty and delivered phospholipids, purified of EPA free a
such as should of triglycerides study absorption diet. the low-fat not with to CaPre ethyl such LOVAZA, of who the believe for some for further showed and the which a in AXc. ester other really PK earlier differentiating absorption. CaPre does facilitate Therapeutics, subjects VASCEPA absorption also superior hemoglobin Unlike the omega-Xs, our omega-X not than state, the the require the LDL in was only as by of Journal a on prescription bioavailability CaPre data ethyl among in measured as ester and recently fatty fasting potentially Bridging drugs of This where DHA. meal significantly on that LOVAZA currently well-demonstrated II published phospholipids rapid patients we deliver This omega-X Phase absorption illustrates of especially Clinical levels remain and benefits to better in compared they blood the was and saw The elevated EPA the market, allow we lowering of clinical but
expected continue to both I'm of that all And We believe Now I our could negative trials. in or today, the low into compliance. of TRILOGY translate dropout our than has pleased want better potentially report rates no to emphasize, safety studies lower dropout rates be effects side patient in the concerns. CaPre to
have strong oil prescribing hard said a the in tend fishy may which tolerable that to can prescription more not physicians research, our In as a hard-gel is taste. stick nasty swallow oil be have it's they be it and fish fish and current well. only capsule, to throat CaPre but packaged may not to omega-Xs be the a in market easier swallow as
XX% report on let compared will as studies. CaPre’s from show studies in at is include placebo. of weeks how between to baseline least XX% proceed triglycerides are And endpoint, statistical to placebo. of from to to XX primary we to to in our with X intended order decrease our the designed TRILOGY and of our line triglycerides CaPre readout need to to after reminder, TRILOGY Phase This power the difference that we're which the results the NDA achieve me Top the least provide a submission a Now data key III explain planning lowering is overall endpoint at a target impact detect a FDA.
line simple have placebo inert is key in secondary which in to in endpoints. are of The late is don't on is results neutral results group. to TRILOGY the or placebo to the XXXX. any include These expect anticipated a that the which we're TRILOGY expected trials after top of line patients biomarkers cornstarch, effect January follow the expected and currently consequently, is release exploratory We using a results X, top of
proceeding endpoints of prior versus the qualifying a triglyceride show been comparison persistence having and to patients effect, additional levels and triglyceride be levels first, out reduction XX, the first will at triglyceride statins be of and statistical also And achieved of reduction plan, in XXX in report of most of secondary effect. now secondary subgroups at is FDA, greater consistency various baseline to significance XXX. study these so positive, measured we'll as reduction the also the analysis that has to primary statistical According following the We which important and endpoints, not the intended currently the to is analyzed endpoints. this with the who will triglyceride to baseline. had stratified show submitted including such baseline than week between to at endpoint CaPre’s exploratory -- patients end include be expect key must triglycerides We'll then XXX important in analyze and which using additional analyze those the using order:
they II tend amount and effect to Phase these Our omega-X together, the statins have And and patients. positive shown that data many studies a increase other lowering can taken when with in triglyceride of omega-Xs. previous synergistic have
determine and if out at subgroup randomized difference the the any such and/or diabetic and hemoglobin requires to important if be from exist. AXc to CaPre then with Secondly, had from statistical The groups, short-acting require power on on LDL then LDL that combining study. reach TRILOGY AXc to patients be and therapies statins LDL protocol report studies will levels one beyond from and and analyses, as results and to CaPre that hope into being finally, we placebo results investigators presented done to incremental respective patients prior HDL, and patients VLDL adequate our physician levels, AXc to by CaPre followed from their hemoglobin put separately TRILOGY both benefited non-HDL-cholesterol, the the we both stabilized hemoglobin will those high It's show Therefore, with with detect which to who LDL standard high AXc. meds. by then hemoglobin note LDL diabetes above care. screening results results the or patients show standard had of to If so, high want
with Acasti end secondary along of expects the and XXXX. analyses numerous completed the March subgroup that endpoints should additional before Now be exploratory remaining various
interest College March, top potentially communicate finalized. all preliminary non-HDL, June. and will data is information hemoglobin in plan And in when analysis at the which to plan these exploratory to of our In and reported line Lipid results will months the including Cardiology on present AXc HDL, all to in of and plan Association the the the TRILOGY more we'll full National as once May in set, to how statistical ahead Association of half American be endpoints and include we the Diabetes of the such American first for meetings results and scientific in addition data, We XXXX, of the LDL-cholesterol others. seek key VLDL, key our present secondary
TRILOGY positive trials awaiting are the given from our the X from the our patients, XXX saw of in results results completion Now of II a Phase total studies. we clinical eagerly we
not and what as LDL, again, And diabetes. Our hemoglobin other such is II AXc, may VLDL, reduction as markers to trifecta refer major this triglycerides a show positive lipid trials Phase only CaPre that but with HDL have patients of effect. also indicated significant effect in a on our we
our Phase designed most had higher the per clinical the elevated due baseline levels mild to enrolled trials the of below that have believe with And magnitude XXX patients when greater patients seen course, of on compared as also moderately III are And XXX. where higher II the triglycerides, perviously based fact the to that all, triglyceride given as disclosed, baseline data we large much the are is typically to and milligrams the trials, our the body Phase high well therapeutic of starting level, levels, significantly reduction triglycerides deciliter triglyceride above omega-X.
per gram an patients studies. per day to Phase range response for received to studies of II drug II important X receive for our is TRILOGY dose This favorable grams on we grams doses from in months, and X The who the weeks. CaPre remain while saw XX X a randomized our X only patients X to given included Phase day will and
has potentially could TRILOGY a impact important address an patients the Phase replicates on safe of blood an lives improve assuming and the millions lipids cardiometabolic with believe well-absorbing And disease. for AXc. have potential our effective, positive market data, therapeutic CaPre that and therefore, II hemoglobin Now we major of omega-X need to
XXX, million study the although we XX States based third-party additional triglycerides the on in recent require CaPre’s elevated patients initial roughly United future. to million data, Additionally, this to XX least one levels will that potential at expand likely believe with in outcome indication above exist to
countries to around We allowed XX-plus additional continue also our world. patents IP patents to in major portfolio already expand adding the by our issued
were matter for recently As until in the patent that the broad and we office European offices. used composition Republic this Europe. the Western the the in an China. in beginning matter This of method noted a of Chilean market important prevalence People's patent of its third to largest Mexican, follows Israelii market and patents the cardiometabolic-related method conference of for China allowance absorbed year, XXXX, are high on safe cover major world. our efficiently More represents and of second we in of by which notice awarded valid by and for in allowance countries at now and June, pharmaceutical is composition hypertriglyceridemia for the received due for patent of year-end used drug previously treatment the announced Acasti, a of of of not call an This but size only patents notices and diseases. both May, effective, also need the the
XXXX. are currently There greenfield valid expands This product clients in well-studied available approved and high-quality, our omega-X market China until and would existing a differentiated it a like therefore, least opportunity drugs no for new and CaPre. represent at patent is
recent III also and of On of for clinical that the this from for The REDUCE-IT. last label positive the is expansion separate a or intention patent near week from we investors TRILOGY discussions. FDA they supplemental to strategic have preparing seeks VASCEPA, timing received NDA AdCom receive for agency's commercialization ideal data the that a a by a so on application note, of over completion questions we for regarding Phase our committee Amarin's announcement or meeting number begin outcome the CaPre, advancement based an trials notification a as advisory of of the hold
want drug position not an potentially really the the are in to will since a would into label input on AdCom this prospective review FDA decision, would data the sense for receive we're to the FDA's an be not discussion the and that FDA of this While that surprised comment label. we the want in first really the KOL It makes class and VASCEPA. expanded
heart Phase TRILOGY, we impacting in our CaPre Having therapeutic this the for said preventing Again, the can data program severe remain TRILOGY with omega-X omega-Xs continue disease. in treating that, hypertriglyceridemia. to potential II and and has our in treating we see important best-in-class play to the if we don't can overall the role patients that confident become we of believe replicate
I'd take prepared remarks, Now a my close our like before address sheet. to I to balance moment
and of $XX.X June As a we of had cash cash, securities. million marketable XXXX, XX, equivalents
This declining. activities, in Phase we clinical and As of completion cash we to prepare achieve And we capitalized submit for will completion the we trials. are our believe the III near III sufficiently beyond is the once currently of burn our successfully CaPre, Phase funding endpoint. that mid-XXXX, III work support our assuming continued to their primary study includes to NDA which plan the Phase FDA
current expansion current July the U.S. our planned is support business X, extends position believe next the received also million cash activities We warrants our sufficient we at in to since proceeds More exercise of $X.X recently, launch approximately and the into additional through from which year. commercial development XXXX. of runway least further June well of
advance of to raise in currently market in III results. We plans have no public our additional the capital Phase
extend our which are, further could We nondilutive considering runway. variety cash strategic and a options, of funding however,
on We an time. at appropriate will front provide this further updates
Finally, partnerships the a pharma potential of companies countries around in world. major key to we commercialization regarding progress number with discussions continue
Assuming our those are expects III gain momentum positive management early next Phase after discussions results to announced. results, year,
that planning We in our and partnerships. our the puts believe negotiate stronger deals. not having Phase CaPre potential targeted III strategy our U.S. through on that That very assumption strategy. from in partnership We're a hand we in focused to said, the dependent bring position us the launch trials is to go-to-market with data a strategy market any much U.S. will
of if right strategic agreements commercial enter only our and those in into are long-term only we shareholders. the believe with interest partners deals will We best the
will I'll QX more discuss in note, the now over to that the call Jean-François, financials detail. on who turn So
